Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy

The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial

The aim of this study is to compare the efficacy and safety of prednisone versus sub-antimicrobial dose doxycycline (50 mg/d) in the treatment of active moderate-severe Graves' Orbitopathy (GO).

Study Overview

• Status: Unknown
• Conditions: Thyroid Associated Opthalmopathies
• Intervention / Treatment: Drug: Prednisone+placebo of Doxycycline; Drug: Doxycycline+placebo of Prednisone

Detailed Description

Graves' orbitopathy is an autoimmune disease characterized by an inflammatory phase followed by fibrosis. Surgery to correct eyelid swelling, proptosis, and diplopia is effective, but can not be done until the inflammatory phase has passed. To arrest the inflammatory phase, several types of immunosuppressive treatments have been investigated. Corticosteroids are the first-choice immunosuppressive treatment, having a successful outcome of 50-70% in patients. However, long time usage of corticosteroids often cause severe side-effects.

Sub-antimicrobial dose doxycycline posses known anti-inflammatory effects that are separate from their antibacterial mode of action. This mode of action has lead to the routine use of sub-antimicrobial dose doxycycline for treating inflammatory or autoimmune diseases, such as rosacea, periodontitis and multiple sclerosis. The mechanism is by inhibiting lymphocyte proliferation and production of colony-stimulating factor, inflammatory cytokines, and immunoglobulins, factors thought to play a role in the orbital autoimmune process. These mechanisms make them, in theory, an attractive option of doxycycline for treating Graves' Orbitopathy. In addition, only few adverse events were reported when doxycycline were administered for 3 months in patients with periodontitis or rosacea.

We propose to compare the effect and safety of sub-antimicrobial dose doxycycline versus prednisone for treating non-sight threatening, moderate-severe, inflammatory GO.

• Study Type: Interventional
• Enrollment (Anticipated): 146
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Miaoli Lin, md; Phone Number: 0086-20-87331537; Email: linml0754@gmail.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100730
      • Recruiting
      • Peking Union Medical College Hospital
      • Contact: Yong Zhong, MD; Phone Number: +86-10-69156114; Email: yzhong_eye@yahoo.com.cn
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Recruiting
      • Zhongshan Ophthalmic Center
    • Shantou, Guangdong, China, 515041
      • Recruiting
      • JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong
      • Contact: Mingzhi Zhang, MD; Phone Number: +86-754-88393501; Email: zmz@jsiec.org
    • Shenzhen, Guangdong, China, 518040
      • Recruiting
      • Shenzhen Eye Hospital
      • Contact: Guiqin Liu, MD; Phone Number: +86-755-23959600; Email: liuguiqin9@yahoo.com.cn
  • Henan
    • Zhengzhou, Henan, China, 450003
      • Recruiting
      • Henan Eye Institue, Henan, China
      • Contact: Liya wang, MD; Phone Number: 0086-13937169191; Email: wangliya55@126.com
  • Hunan
    • Changsha, Hunan, China, 410011
      • Recruiting
      • The second Xiangya Hospital of Central South University
      • Contact: Wei Xiong, MD; Phone Number: 0086-138-0846-9035; Email: weixiong420@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Confirmed diagnosis of Graves' Orbitopathy (as defined by Bartley and Gorman)

  • Eyelid retraction (upper eyelid margin at or above the superior corneoscleral limbus in primary gaze without frontalis muscle contraction) in association with any one of the following:

    • Thyroid dysfunction or abnormal regulation (increased serum thyroxine or triiodothyronine level, decreased serum thyroid stimulating hormone level, absence of thyroid radioiodine uptake suppression after administration of triiodothyronine, or the presence of thyroid stimulating immunoglobulins in serum)
    • Exophthalmos
    • Extraocular muscle involvement (restrictive myopathy or objective evidence of enlarged muscles)
    • Optic nerve dysfunction (abnormal visual acuity, color vision, pupillary reaction or perimetry not attributable to other causes) OR

  • Thyroid dysfunction or abnormal regulation in association with any one of the following:

    • Exophthalmos
    • Extraocular muscle involvement
    • Optic nerve dysfunction
• Moderate-severe GO According to EUGOGO statement, patients with moderate-severe GO usually have any one or more of the following：lid retraction≥2mm, moderate or severe soft tissue involvement, exophthalmos≥3mm above normal for race and gender, inconstant, or constant diplopia.
• Clinical activity score ≥ 3
• Being euthyroid for at least 1 months before the date of inclusion
• Must be able to swallow tablets
• Written informed consent is obtained

Exclusion Criteria:

• Mild Graves' Orbitopathy
• Sight-threatening Graves' Orbitopathy
• Clinical activity score < 3
• Previous treatment for GO Oral steroids, intravenous steroids, radiotherapy
• Pregnant females as determined by positive (serum or urine) human chorionic gonadotrophin (hCG) test at screening or prior to dosing, or lactating females
• Uncontrolled diabetes or hypertension
• History of mental / psychiatric disorder
• Hepatic dysfunction (Albumin (Alb) , Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)
• Renal impairment (Urea and Creatinine levels must be within normal range)
• Doxycycline or Prednisone allergy or intolerance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Prednisone+placebo of Doxycycline; Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.	Drug: Prednisone+placebo of Doxycycline; Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks; Other Names: deltacortisone
EXPERIMENTAL: Doxycycline+placebo of Prednisone; Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.	Drug: Doxycycline+placebo of Prednisone; Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.; Other Names: Dolotard; Tibirox; Biomycin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall treatment response	Overall treatment response was graded as: improvement, deterioration, and no success.; Improvement, when at least one major criteria or two minor criteria were achieved, in absence of deterioration of any criterion in that observed eye.Three major criteria were: improvement in diplopia grade (disappearance or change in grade); improvement of ≥8 degrees in any direction of eye movements; reduction of three points or more in CAS. Four minor criteria were: reduction of 2 mm or more in eyelid aperture; reduction of 2 mm or more in proptosis; improvement in grade of soft tissue swelling; decrease in CAS by at least two points.; Deterioration, defined as occurrence of DON, and/or worsening of soft tissue swelling, and/or worsening of diplopia, and/or an increase of ≥2 mm in lid aperture, and/or an increase of ≥2 mm in proptosis, and/or a decrease of ≥8 degrees in duction.; No success was defined if there was no change or the changes did not reach the improvement criteria.	24 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
• Health related quality of life questionnaires (GO-QoL)	24 weeks
• Safety and tolerability as assessed by adverse events, vital signs	48 weeks
• Quantitative changes of rectus diameter measured by MRI scan	24 weeks
Relapse	48 weeks

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Investigators: Principal Investigator: Liya Wang, MD, Henan Eye Institue, Henan, China; Principal Investigator: Luosheng Tang, MD, The second xiangya hospital of central south university, Hunan, China

Publications and helpful links

Helpful Links

• U.S. FDA Resources
• MedlinePlus related topics: Antibiotics Eye Diseases Thyroid Diseases
• Genetics Home Reference related topics: Lenz microphthalmia syndrome oculofacioc

Study record dates

Study Major Dates

• Study Start: November 1, 2012
• Primary Completion (ANTICIPATED): January 1, 2016
• Study Completion (ANTICIPATED): January 1, 2016

Study Registration Dates

• First Submitted: December 2, 2012
• First Submitted That Met QC Criteria: March 10, 2013
• First Posted (ESTIMATE): March 12, 2013

Study Record Updates

• Last Update Posted (ESTIMATE): December 10, 2013
• Last Update Submitted That Met QC Criteria: December 7, 2013
• Last Verified: December 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Eye Diseases; Endocrine System Diseases; Genetic Diseases, Inborn; Thyroid Diseases; Eye Diseases, Hereditary; Graves Disease; Exophthalmos; Orbital Diseases; Goiter; Hyperthyroidism; Graves Ophthalmopathy; Physiological Effects of Drugs; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Anti-Bacterial Agents; Antiprotozoal Agents; Antiparasitic Agents; Antimalarials; Prednisone; Doxycycline
• Other Study ID Numbers: 5010-doxy